Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates.

A series of organoruthenium(II) chlorido complexes with fluorinated O,O-ligands [(η(6)-p-cymene)Ru(F3C-acac-Ar)Cl] (1a-6a) and their respective 1,3,5-triaza-7-phosphaadamantane (pta) derivatives [(η(6)-p-cymene)Ru(F3C-acac-Ar)pta]PF6 (1b-6b) were synthesized and fully characterized in both solution and solid state. All complexes were inactive against nonmalignant keratinocytes but displayed variable activity against cancer cell models (ovarian, osteosarcoma). Compounds with a ligand containing the 4-chlorophenyl substituent (6a and 6b) exhibited the strongest anticancer effects. Despite a marginally lower cellular Ru accumulation compared to the chlorido complexes, pta analogues showed higher activity especially in the osteosarcoma model. Reduction of glutathione levels by buthionine sulfoximine (BSO) significantly enhanced the activity of all compounds with the most pronounced effects being observed for the pta series resulting in IC50 values down to the nanomolar range. While all chlorido complexes potently induce reactive oxygen species, DNA damage, and apoptosis, the respective pta compounds widely lacked ROS production but blocked cell cycle progression in G0/G1 phase.

[1]  P. Chakravarty,et al.  Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines , 2014, British Journal of Cancer.

[2]  W. Berger,et al.  NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application , 2014 .

[3]  I. Mlinarič-Raščan,et al.  Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity. , 2014, Dalton transactions.

[4]  M. Mozzicafreddo,et al.  Arene-ruthenium(II) acylpyrazolonato complexes: apoptosis-promoting effects on human cancer cells. , 2014, Journal of medicinal chemistry.

[5]  T. Mohr,et al.  The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo☆ , 2013, European journal of cancer.

[6]  T. Mohr,et al.  Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. , 2013, Biochemical pharmacology.

[7]  P. Sadler,et al.  Next-generation metal anticancer complexes: multitargeting via redox modulation. , 2013, Inorganic chemistry.

[8]  Nicolas P E Barry,et al.  Exploration of the medical periodic table: towards new targets. , 2013, Chemical communications.

[9]  Hong Wang,et al.  Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers , 2013, Journal of Hematology & Oncology.

[10]  E. Meggers,et al.  Metal complex catalysis in living biological systems. , 2013, Chemical communications.

[11]  I. Turel,et al.  Novel Organoruthenium(II) β-Diketonates as Catalysts for Ortho Arylation via C–H Activation , 2013 .

[12]  V. Moreno,et al.  Preparation of new half sandwich ruthenium arene complexes with aminophosphines as potential chemotherapeutics. , 2012, Journal of inorganic biochemistry.

[13]  D. Marko,et al.  Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. , 2012, Journal of medicinal chemistry.

[14]  D. Miklavčič,et al.  Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex , 2012 .

[15]  P. Sadler,et al.  Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity , 2012, JBIC Journal of Biological Inorganic Chemistry.

[16]  P. Sadler,et al.  Designing organometallic compounds for catalysis and therapy. , 2012, Chemical communications.

[17]  P. Sadler,et al.  Organometallic ruthenium and iridium transfer-hydrogenation catalysts using coenzyme NADH as a cofactor. , 2012, Angewandte Chemie.

[18]  W. Berger,et al.  Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds , 2012, JBIC Journal of Biological Inorganic Chemistry.

[19]  M. Brand,et al.  The Mechanism of Superoxide Production by the Antimycin-inhibited Mitochondrial Q-cycle* , 2011, The Journal of Biological Chemistry.

[20]  M. Jakupec,et al.  Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial Quinolones , 2011, Organometallics.

[21]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[22]  P. Dyson,et al.  Metabolization of [Ru(η6-C6H5CF3)(pta)Cl2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand , 2010, JBIC Journal of Biological Inorganic Chemistry.

[23]  E. Antonarakis,et al.  Ruthenium-based chemotherapeutics: are they ready for prime time? , 2010, Cancer Chemotherapy and Pharmacology.

[24]  J. Barton,et al.  Exploring the cellular accumulation of metal complexes. , 2010, Dalton transactions.

[25]  Xiuping Chen,et al.  2′,7′-Dichlorodihydrofluorescein as a fluorescent probe for reactive oxygen species measurement: Forty years of application and controversy , 2010, Free radical research.

[26]  M. Jakupec,et al.  Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. , 2009, Chemistry.

[27]  R. Filler,et al.  Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. , 2009, Future medicinal chemistry.

[28]  P. Langer,et al.  First synthesis of functionalized 5-aryl-3-(trifluoromethyl)phenols by regioselective [3+3] cyclocondensations of 1,3-bis(silyloxy)-1,3-butadienes with 3-aryl-3-silyloxy-1-trifluoromethyl-2-en-1-ones , 2009 .

[29]  Anthony L. Spek,et al.  Structure validation in chemical crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.

[30]  A. Casini,et al.  Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. , 2008, Journal of inorganic biochemistry.

[31]  Anna F. A. Peacock,et al.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.

[32]  C. S. Allardyce,et al.  Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)]. , 2008, Journal of inorganic biochemistry.

[33]  P. Sadler,et al.  Catalytic organometallic anticancer complexes , 2008, Proceedings of the National Academy of Sciences.

[34]  P. Dyson,et al.  The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways , 2008, JBIC Journal of Biological Inorganic Chemistry.

[35]  Carsten A. Vock,et al.  Influence of the Diketonato Ligand on the Cytotoxicities of [Ru(η6-p-cymene)(R2acac)(PTA)]+ Complexes (PTA = 1,3,5-triaza-7-phosphaadamantane) , 2008 .

[36]  C. Pirker,et al.  Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). , 2007, Biochemical pharmacology.

[37]  A. Bergamo,et al.  Ruthenium complexes can target determinants of tumour malignancy. , 2007, Dalton transactions.

[38]  Anna F. A. Peacock,et al.  Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding. , 2007, Chemistry.

[39]  P. Sadler,et al.  Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. , 2006, Journal of medicinal chemistry.

[40]  Robin Taylor,et al.  Mercury: visualization and analysis of crystal structures , 2006 .

[41]  T. Kodama,et al.  Activation of mitogen-activated protein kinases by lysophosphatidylcholine-induced mitochondrial reactive oxygen species generation in endothelial cells. , 2006, The American journal of pathology.

[42]  P. Dyson,et al.  In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.

[43]  P. Carroll,et al.  Pentamethylcyclopentadienyl ruthenium(II) complexes of para-substituted N-(pyrid-2-ylmethylene)-phenylamine ligands: syntheses, spectral and structural studies , 2005 .

[44]  W. Berger,et al.  Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) , 2005, Journal of Pharmacology and Experimental Therapeutics.

[45]  J. Cummings,et al.  Inhibition of cancer cell growth by ruthenium(II) arene complexes. , 2001, Journal of medicinal chemistry.

[46]  W. Berger,et al.  Expression of the major vault protein LRP in human non‐small‐cell lung cancer cells: Activation by short‐term exposure to antineoplastic drugs , 2000, International journal of cancer.

[47]  M. Walton,et al.  Characterisation of the P53 status, BCL‐2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines , 1998, International journal of cancer.

[48]  Maria Cristina Burla,et al.  SIR92 – a program for automatic solution of crystal structures by direct methods , 1994 .

[49]  H. Koeffler,et al.  Rearrangement of the p53 gene in human osteogenic sarcomas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[51]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[52]  M. Jakupec,et al.  Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. , 2009, Journal of analytical atomic spectrometry.

[53]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[54]  C. S. Allardyce,et al.  [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .